A flavoprotein mechanism appears to prevent an oxygen-dependent inhibition of cGMP-associated nitric oxide-elicited relaxation of bovine coronary arteries.
The redox state of the heme of soluble guanylate cyclase (sGC) may regulate the sensitivity of vascular tissue to nitric oxide (NO). In this study, diphenyliodonium (DPI) is used as an inhibitor of flavoprotein oxidoreductases to examine their potential role in the expression of NO-elicited cGMP-associated arterial relaxation and sGC stimulation. The relaxation of endothelium-removed bovine coronary arteries (BCAs) precontracted with 30 mmol/L KCl to the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) or to NO is markedly suppressed by 10 micromol/L DPI under an atmosphere of 21% O(2) (5% CO(2)). In contrast, DPI has minimal effects on the relaxation to SNAP under 95% N(2) (5% CO(2)). If BCAs are treated with DPI under 21% O(2) and then exposed to the hemoprotein reductant sodium dithionite (1 mmol/L) under N(2), there is a partial reversal of the inhibitory effects of DPI compared with BCAs that were not treated with dithionite. DPI did not inhibit relaxation elicited by 8-bromo-cGMP or forskolin. Increases in tissue cGMP levels stimulated by SNAP were eliminated by pretreatment of BCAs with DPI under 21% O(2) but not under N(2). Activation of sGC by SNAP in BCA homogenate was also eliminated when vessels were pretreated with 10 micromol/L DPI under 21% O(2), but DPI did not have an inhibitory effect when directly added to the assay of sGC activity. These observations are consistent with a flavoprotein-dependent oxidoreductase functioning to prevent the expression of a novel O(2)-dependent process from oxidizing the heme on sGC and inhibiting NO-elicited cGMP-mediated BCA relaxation.
Iesaki
T
T
Department of Physiology, New York Medical College, Valhalla, NY 10595, USA.
Gupte
S A
SA
Wolin
M S
MS
D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology; D002417:Cattle; D005576:Colforsin / Q000494:pharmacology; D003331:Coronary Vessels / Q000187:drug effects*; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005420:Flavoproteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006420:Hemeproteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009126:Muscle Relaxation / Q000187:drug effects; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009603:Nitroso Compounds / Q000494:pharmacology; D009861:Onium Compounds / Q000494:pharmacology; D010084:Oxidation-Reduction; D010088:Oxidoreductases / Q000037:antagonists & inhibitors / Q000502:physiology*; D010100:Oxygen / Q000502:physiology*; D013431:Sulfates / Q000494:pharmacology
D001713:Biphenyl Compounds; D005420:Flavoproteins; D006420:Hemeproteins; D020030:Nitric Oxide Donors; D009603:Nitroso Compounds; D009861:Onium Compounds; D013431:Sulfates; C031291:diphenyliodonium; D005576:Colforsin; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; C024942:S-nitrosopenicillamine; D010088:Oxidoreductases; D006162:Guanylate Cyclase; D006152:Cyclic GMP; C004850:sodium dithionate; D010100:Oxygen